'standard' strains used by researchers possess polymorphism rates of ~1 in every 100 bases 22 . These variations could affect the target-binding specificity, as even a single mismatch in the target site could negatively affect sgRNA activity 23 . To improve our target efficiency, it would be advantageous to use a strain for which all variations are known. We therefore created NHGRI-1, a highly fecund strain for which nearly all variations in the founding parents have been documented by high-throughput sequencing. We now use the variation data (and the fish themselves) to select the target sites that avoid polymorphisms, helping to ensure success on the first attempt 19 . The variation data are also included in the UCSC Genome Browser public hub, together with the predicted CRISPR/Cas9 target site tracks, allowing for integration of the data.
We did not have to alter the well-established techniques for mRNA injections in zebrafish embryos, but we did develop a Microsoft Excel-based calculator, CRISPR-CALC (http://research. nhgri.nih.gov/CRISPRz/downloads/CRISPR_CALC.xlsx), to simplify the calculations for the amount of sgRNA and Cas9 mRNA to be injected 20 .
Because target mutagenesis efficiency can vary so widely, it was essential for us to develop a rapid method for evaluating sgRNA targeting efficiency. There are several methods for evaluating the sgRNA activity, the most common being the PCR amplification of the target site, followed by subcloning and sequencing. We developed a scalable, high-throughput and high-resolution CRISPR-STAT to evaluate the target activity in injected embryos using fluorescence PCR 20 . We collect eight uninjected and eight injected embryos 24-48 h after injection and run a 'three-primer' fluorescence PCR using gene-specific primer pairs and a fluorescently tagged primer. The resulting fluorescently tagged amplicons are then separated using capillary electrophoresis on a Genetic Analyzer 3130xl or 3730xl. We then compare the fragment size peak(s) of injected and uninjected embryos to detect the fold reduction of wild-type (WT)-sized alleles. We found that evaluating the somatic activity of the injected target maximized the likelihood of obtaining a genetic mutant. All targets for which somatic activity was detected transmitted mutations through the germline.
Once sgRNA efficiency has been determined, the final step we needed to develop was rapid and simple genotyping of the F 1 progeny. We developed a PCR-based protocol, using the same techniques as those of CRISPR-STAT, that robustly and rapidly identified frameshift mutations, and could, in parallel, be sequenced using indexed samples and 'next-generation' sequencing 17 .
Overview of the procedure
The experimental workflow is summarized in Figure 1 and consists of zebrafish target design and sgRNA synthesis; microinjection of sgRNA/Cas9; target somatic activity validation; and screening of mutants in the germline.
Target selection and sgRNA synthesis. We recommend selecting a minimum of two target sites; our data show that ~85% of the targets are sufficiently active to generate germline mutations 17 , and thus use of two targets ensures success in almost all cases. We also prefer to target a known functional domain of the protein whenever possible, or early exons common to all known splice variants. To select sgRNA sequences, we use the UCSC Genome Browser and our predicted sgRNA targets for synthesis with either T7 or SP6 RNA polymerase opting for guides that avoid polymorphisms and have as few predicted off-targets as possible (<500 preferred).
For sgRNA synthesis, we use a cloning-free, oligo-based method (Fig. 2a) . This requires a target-specific DNA oligo (top-strand oligo, 55-57 nt) and a 'generic' DNA oligo for the guide RNA (bottomstrand Ultramer, 80-nt). The target-specific oligo contains a 17-nt-long T7 or SP6 promoter, the 18-20-nt target sequence and finally a 20-nt sequence complementary to the guide RNA. The two oligos are annealed and extended with DNA polymerase, and the resulting product serves as a template for in vitro transcription. This method can be used to synthesize 96 sgRNAs in 3-4 h.
Microinjection.
The sgRNA and Cas9 mRNA (or protein) are co-injected into single cell-stage embryos. We routinely co-inject 25-50 pg sgRNA per target and 150-300 pg Cas9 mRNA. Injection of 50 pg sgRNA/150 pg Cas9 or 25 pg sgRNA/300 pg Cas9 resulted in similar germline transmission efficiencies. Alternatively, commercially available Cas9 protein can also be used, We found comparable somatic mutagenesis efficiencies using Cas9 protein or injecting Cas9 mRNA into the cell cytoplasm. To make this pipeline high-throughput, we inject sgRNA/Cas9 mRNA into the yolk. If the aim, however, is to observe phenotypes in the injected embryos, we recommend injecting directly into the cell; this typically results in an increase in mutagenic efficiency and an increased chance of simultaneously mutation of both alleles. However, cell injections are not recommended if the goal is germline transmission, as targeting essential genes with high mutagenesis efficiencies might result in poor survival of the founder fish.
Screening and verification of germline mutations. After evaluating the sgRNA activity in somatic tissues, the remaining injected embryos are raised to adulthood. We typically screen 6-8 founder fish for germline mutations using our three-primer fluorescence PCR method (Fig. 2b) . Each founder (F 0 ) is either outcrossed with a WT fish or inbred with another founder, and then 7-8 embryos from each outcrossed pair or 16-24 embryos from each inbred pair are screened for mutations in the F 1 generation. We have previously demonstrated the use of fluorescence PCR in screening germline mutations in a high-throughput manner 17, 24 . NHEJ generates small indels that the fluorescence PCR can readily detect, allowing us to quickly decide which founders to keep for raising mutant F 1 progeny. We typically raise F 1 embryos for 2-3 independent alleles that carry frameshift mutations. Although fluorescence PCR is a robust method of quickly screening mutants, it does not yield the exact nature of the lesions; the screened alleles must be sequenced to get the precise mutation data. Sequencing also avoids the risk of wrongly assuming any naturally occurring indel variation in the target area is an introduced mutation. Therefore, we developed a multiplexed barcoded next-generation sequencing pipeline that allows pooling of amplicons from up to 96 different embryos for a single target 17 . This sequencing pipeline uses the same gene-specific primer set used in fluorescence PCR (Fig. 2b) , saving time and expense.
Use of fluorescence PCR for genotyping. The F 1 adults (and subsequent generations) are genotyped after fin amputation and performance of the same 'three-primer' fluorescence PCR method as described above. Phenotyping is done in the F 2 generation by inbreeding two heterozygous F 1 adults, and the phenotype-genotype correlation is established by genotyping again using fluorescence PCR and observing the presence or absence of the WT and mutant alleles. We also demonstrated that phenotyping can be done in the F 1 generation, and the mutants (compound heterozygotes) can be phenotyped in a nonMendelian, but robust, manner 17 . On the basis of our data, the average rate of obtaining compound heterozygotes by inbreeding two injected founder fish is 11%, but when the founders are prescreened and only positive founders are inbred, the average rate is ≈36% (ref. 17 ).
Advantages and limitations
The mutagenesis pipeline described here is inexpensive, of high throughput and 6-7× more efficient than TALEN or ZFN in generating germline mutations 17 . This pipeline has been used for the generation of mutants for more than 500 targets. The primary goal of this pipeline is to generate knockout mutations; however, this method could also be used to select efficient sgRNAs using CRISPR-STAT for targeted knock-in experiments.
As with all methods, our approach also has some limitations. The frequency of variants (~1 in 100) in the zebrafish genome means that fluorescence PCR used to rapidly identify mutations can generate false-positive data. We therefore recommend sequence confirmation of all identified mutations to verify the precise nature of detected indels. As not every lab has direct access to a capillary electrophoresis instrument, DNA samples can be submitted to a sequence analysis facility (commercial or in-house core) for fluorescence PCR analysis and Sanger sequencing. We also recommend using variant data from the zebrafish genome when designing primers, in order to avoid known variants in the target amplicons.
Another limitation is the number of useful targets in the zebrafish genome. When using T7 or SP6 to synthesize the sgRNA, target sequences must start with GG (T7) or GA (SP6). Furthermore, CRISPR/Cas9 requires that the target site precede an NGG protospacer adjacent motif (PAM) sequence (not included in the actual target sequence). The PAM sequence requirement can be relaxed by using alternative versions of Cas9 (from different bacteria with different PAM requirements), and the 5′ GG or GA requirement can be addressed by using targets of different length (19 nt and 18 nt) 25, 26 , chemically synthesizing the sgRNA or using the CRISPR-associated endoribonuclease Csy4 to trim off leader sequences 27 .
A generally recognized limitation of CRISPR/Cas9-based genome editing is off-target cleavage. We previously detected a germline mutation in one off-target site out of 25 predicted offtarget sites tested 17 . Off-target cleavage is generally not a major concern in zebrafish, as outcrossing of animals typically segregates unlinked mutations. However, off-target cleavage can be reduced by using either a 'nickase' version of Cas9 that requires two adjacent sgRNAs 28 (increasing specificity) or a truncated guide RNA 29 . We have generated a zebrafish codon-optimized version of the Cas9 nickase plasmid (pT3TS-nls-zCas9-nlsD10A; Addgene, cat. no. 78634); however, we have not systematically compared its on-target and off-target mutagenic activities with 
Alternative methods
In zebrafish, two other targeted mutagenesis tools, ZFNs and TALENs, are being used 18 . We compared the germline transmission efficiencies of ZFNs, TALENs and CRISPR/Cas9 in zebrafish. The average germline transmission efficiency for CRISPR/Cas9 was 28% using this protocol, as compared with 5% and 4%, respectively, for ZFNs and TALENs 17 . CRISPR/Cas9 is not only 6-7 times more effective, but it can also be used effectively in a high-throughput manner. The higher germline transmission efficiencies of CRISPR/Cas9 reduce the animal husbandry work, which not only increases the throughput but also saves time and makes it more affordable. Multiplexed CRISPR/Cas9 mutagenesis (i.e., targeting multiple loci simultaneously) can be achieved by adding additional sgRNAs to the injection mix. This is much more difficult with ZFNs or TALENs because of costs and the time associated with making them. In terms of mutagenic diversity, ZFNs generate deletions, insertions and complex mutations (i.e., a mixture of deletion and insertion), and TALENs mostly generate deletions or complex mutations with fewer simple insertions. CRISPR/Cas9 generates deletions, insertions and complex mutations similar to those generated by ZFNs 17, 32 .
Experimental design
Choice of Cas9. Multiple plasmids encoding Cas9 are available; we have not tested all of them, but we recommend using the zebrafish codon-optimized Cas9 by Jao et al. 16 . The Cas9 protein available from multiple commercial sources can also be used. We find the mutagenesis rates for Cas9 mRNA and Cas9 protein to be comparable (data not shown). Moreno-Mateos et al. 26 used a Cas9-nanos version, which preferentially targets the germ cells. Although its activity is lower than that of WT Cas9, it is active enough to generate germline mutations with a reasonable efficiency without harming the somatic tissue. We have not directly tested this option, so we present it only as a possible approach.
Controls.
We use sgRNA targeting the tyrosinase (tyr) gene as a positive control (Supplementary Table 1 ). The phenotype associated with the tyr knock-down is reduced pigmentation, which can easily be observed at 48 hours post fertilization (hpf). The tyr sgRNA can also be used to check the quality of Cas9 mRNA, and we recommend testing every new batch of Cas9 mRNA with this target. 18 .
MaterIals

REAGENTS
2| Select the 'ZebrafishGenomics' track and click 'Connect', and then select a genome assembly (e.g., danRer10 or danRer7; danRer10 is recommended).
3|
The ZebrafishGenomics track will be added. Select one of the following three options: All targets (all targets), GA targets (N18-20) (CRISPR/Cas9 targets that start with GA; for use with an SP6 promoter) and GG targets (N18-20) (CRISPR/Cas9 targets that start with GG; for use with a T7 promoter) (supplementary Fig. 1) . We recommend selecting the GG targets if possible, as T7 polymerase is more efficient than SP6 for RNA synthesis.
4| Search for your gene, and select a target in the region of interest.
5|
Click on the target to obtain the target sequence. The targets are color-coded according to sequence length (gray = 20 nt, blue = 19 nt, orange = 18 nt) and score (the darker the color, the lower the score-i.e., fewer predicted off-targets). A target in the region of interest with the lowest score is preferred.  crItIcal step It is best to select a minimum of two targets, as only 85% of sgRNAs are active enough for significant germline transmission 17 .
6|
Obtain the selected target sequence; add the T7 promoter (for GG targets) or SP6 promoter (for GA targets) sequence to the 5′ end of the target sequence, and a 20-nt overlapping sequence at the 3′ end. 
7|
Design primers to amplify a 200-to 325-bp product surrounding the targeted region of the gene, with the CRISPR/Cas9 target roughly in the middle of the amplicon (Fig. 2b) .  crItIcal step If possible, design primers in an exon sequence. If an intronic sequence must be used, avoid repetitive sequences and stretches of the same nucleotide in order to avoid off-target priming or multiple target artifacts. It is very important that the WT PCR products give a single peak when performing fluorescence PCR, in order to avoid false positives.
8|
Add the M13F sequence (5′-TGTAAAACGACGGCCAGT-3′) to the 5′ side of the forward primer and a pigtail sequence (5′-GTGTCTT-3′) to the 5′ side of the reverse primer (Fig. 2b) . The pigtail sequence was first described by Brownstein et al. 33 for accurate genotyping of human DNA samples using short tandem repeat mapping and was adopted by Sood et al. 24 for the genotyping of indels generated by targeting nucleases in zebrafish.
Primers will be as follows:
Forward: 5′-TGTAAAACGACGGCCAGT (n) 18-22 -3′
Reverse: 5′-GTGTCTT (n) 18-22 -3′
9|
Order the top-strand oligos (from Step 6), fluorescence PCR primers (from Step 8), M13-FAM primer (see Reagents) and universal bottom-strand Ultramer (see Reagents). Order top-strand oligos either as 10 mM scale (desalted) or 500-picomole scale (available in a 96-well-plate format).
In vitro transcription and purification of Cas9 mrna • tIMInG 1 d  crItIcal Steps 10-19 and 20-27 can be carried out in parallel to save time. 10| Digest 5 µg of circular pT3TS-nls-zCas9-nls plasmid DNA with XbaI in a 50-µl total volume at 37 °C for 2 h.
11|
Purify the digested DNA with the QIAquick PCR Purification Kit according to the manufacturer's protocol, and verify digestion on a 1% (wt/vol) agarose gel in TAE buffer using standard protocols. A successful digest should produce a single 7.3-kb band (Fig. 3a, lane 2) . 
12|
14|
Incubate the reaction at 37 °C for 2 h.
15| Add 1 µl of TURBO DNase (included in the mMessage mMachine T3 Transcription Kit) and mix well.
16|
Incubate the reaction at 37 °C for 15 min.
17|
Purify the RNA transcription reaction using the RNA Clean and Concentrator-5 Kit according to the manufacturer's instructions, with an elution volume of 20 µl of nuclease-free water.
18|
Quantify the RNA using a NanoDrop spectrophotometer. The concentration should be >500 ng/µl, with an A 260/280 ratio range of 2.0-2.3. ? trouBlesHootInG 19| Run ~500 ng of purified RNA on a 1% (wt/vol) agarose gel in TAE buffer using standard protocols. A successful transcription should produce a band running at ~1.6 kb (Fig. 3a, lane 3) . Divide Cas9 mRNA into 5-µl aliquots with a concentration >500 ng/µl. ? trouBlesHootInG  pause poInt Cas9 mRNA aliquots can be stored at −80 °C for months. Multiple freeze-thaw cycles are not recommended; therefore, thaw only the required number of aliquots for each use. Target-specific oligos are annealed and extended with the generic gRNA oligo, and the assembled products are run on a 2.5% (wt/vol) agarose gel. Correctly assembled oligos should run at 117-120 bp (lanes 1, 2). Bottom-strand oligo (oligo2) or top-strand oligo will run at much smaller sizes (lanes 3, 4). (c) The assembled oligos were used as a template for an in vitro transcription reaction. The sgRNAs are run on a 2.5% (wt/vol) DNA agarose gel. A successful sgRNA synthesis will produce two bands between 100 and 200 bp. The higher-size band is because of the secondary structure of the sgRNA (lane 2), and it will disappear upon heating at 65 °C (lane 1); incorrect oligo assembly will not yield any RNA (lanes 3 and 4).
synthesis of guide rna using cloning-free methods • tIMInG 4-5 h 20|
Set up the oligo annealing reactions using option A for single sgRNA synthesis or option B for multiplex sgRNA synthesis. 'Top strand' refers to the oligo that contains the target site. 'Bottom strand' refers to the universal Ultramer that will add the crRNA-tracRNA sequences that Cas9 will recognize. 22| Run 3 µl of the oligo assembly reaction along with a 1-kb-plus DNA ladder on a 2.5% (wt/vol) agarose gel in TAE buffer using standard protocols. The expected size of a correctly assembled oligo is 117-120 bp (Fig. 3b, lanes 1 and 2) . ? trouBlesHootInG 23| After gel verification that the product is of the correct size, set up the sgRNA synthesis reaction using the NEB T7 High Yield RNA Synthesis Kit (option A) or MAXIScript SP6 Transcription Kit (option B), depending on the promoter sequence in the assembled oligo. 26| Purify the RNA synthesis reaction using the RNA Clean and Concentrator-5 Kit according to the manufacturer's instructions, and elute with 20 µl of nuclease-free water. Alternatively, use 1/10 volume of 3 M sodium acetate (pH 5.2) and 2.5 volumes of ethanol to precipitate the sgRNA. The concentration should be >100 ng/µl, with an A 260/280 ratio range of 2.0-2.3. Both methods-i.e., ethanol precipitation and purification using the kit-work well, with the ethanol precipitation being the cost-effective approach.
? trouBlesHootInG 27| Run ~500 ng on a 2% (wt/vol) agarose gel in TAE buffer using standard protocols. Two bands of ~100-and ~200-bp size indicate successful sgRNA synthesis. The 200-bp band is due to the secondary structure of the sgRNA (Fig. 3c, lanes 1 and 2) ? trouBlesHootInG  pause poInt sgRNA can be stored at −80 °C for several months.
Microinjection workflow • tIMInG 2 h 28|
Set up matings of Zebrafish the night before scheduled injections.
29|
On the morning of injections, set up the injection apparatus.  crItIcal step Each embryo should be injected with 50 pg sgRNA and 300 pg Cas9 mRNA for single targets or 25 pg sgRNA and 300 pg Cas9 mRNA for multiplex targeting. To avoid toxicity, the total amount of mRNA injected per embryo should not exceed 500 pg.
30|
Load the mixed RNA solution into a capillary injection needle and inject 1.4 nl per embryo (Fig. 4) into ~100 embryos. Injections into the yolk are faster and usually sufficient for generating a mutant; however, we have observed that injection into the cell results in higher mutagenic activity ( Fig. 5a-f) . Cell injections are also recommended if it is desirable to observe the phenotype in the injected embryos.
31| Save uninjected embryos from the same clutch as controls, and place embryos into a 28.5 °C incubator.
32| At 3-6 hpf, remove the unfertilized and injectiondamaged embryos. Place the embryos back into the 28.5 °C incubator. 35| Using a 96-well plate, place 1 embryo into each well, using one column for each injection group.
33|
36|
Extract genomic DNA from the embryos as described in Box 2.  crItIcal step If the embryos are still within chorions, place the plate into a −20 °C freezer until the samples are completely frozen (~30 min). Allow them to thaw at RT and then proceed with genomic DNA extraction. This freeze-thaw cycle will burst the chorions, allowing the solutions access to the embryo. Box 2 | Extraction of genomic DNA from zebrafish embryos/fin tissues.
• tIMInG 45 min Genomic DNA can be prepared using either the modified Sigma-Aldrich Extract-N-Amp extraction procedure (method A) or the sodium hydroxide extraction procedure (method B). The procedures below are written for extraction of genomic DNA from embryos; for fin tissues, simply double the volumes. We have used both methods and obtained similar results. However, we prefer the Sigma-Aldrich Extract-N-Amp extraction method because it uses ready-made solutions and is more consistent across samples, whereas a different number of sodium hydroxide extractions may be required to fully dissolve tissues in different samples. However, the sodium hydroxide extraction procedure is the more cost-effective approach. 38| Add 6 µl of primer mix to a 100-µl aliquot of PCR master mix.  pause poInt PCR products can be frozen at −20 °C for up to a week.
42| Make 1 ml of a 1:50 dilution of GeneScan 400HD ROX using Hi-Di Formamide.
43| Add 10 µl of the ROX/Hi-Di mixture to a 96-well plate that will fit onto an ABI 3130xl or 3730xl genetic analyzer.
44| Add 2.5 µl of the fluorescence PCR product (Step 41) to the plate containing the ROX/Hi-Di mixture.
45|
Heat the plate at 95 °C for 5 min using a thermocycler.
46|
Load the plate onto an ABI 3130xl or 3730xl genetic analyzer and run using the CRISPR-STAT module parameters (supplementary table 2).
47|
After the run is complete, analyze the data using the GeneMapper Software package to determine the CRISPR/Cas9 mutagenesis activity (Fig. 5g-i) .
? trouBlesHootInG 48| Grow injection groups in which embryos display high or low activity (from here on referred to as F 0 ) for founder screening.
Growing the embryos with high activity will make recovering germline mutations fairly easy by screening <10 F 0 fish. Recovering germline mutations from low-activity targets may require screening of additional F 0 fish. 51| Extract genomic DNA as described in Box 2.
52| Add 60 µl of primer mix (
Step 37) to a 1-ml aliquot of PCR master mix. Note: The volumes given here are for 96 samples and can be adjusted depending upon the number of samples being processed.
53|
Set up the reaction and run fluorescence PCR and capillary electrophoresis as described in Steps 39-45.
54|
Load the plate onto an ABI 3130xl or 3730xl genetic analyzer and run the reaction using the Fragment Analysis module parameters (supplementary table 2 ).
55|
After the run is complete, analyze the data using GeneMapper Software package to determine CRISPR/Cas9-induced mutations in the progeny of each F 0 fish. Each sample should give a peak of the expected size (WT peak). Some or all samples may give a second peak, indicating the presence of a mutant allele. The difference in size between the WT peak and the mutant peak indicates the size of the insertion (larger than the WT peak) or deletion (smaller than the WT peak) generated by CRISPR/Cas9 (Fig. 6) .
? trouBlesHootInG 56| Choose F 1 embryos with frameshift mutations (not multiples of 3) to establish knockout mutant lines. Ideally establish two lines by growing F 1 embryos from two independent founders.  crItIcal step Perform sequence validation of the chosen mutant alleles, as it is possible to have the same size mutation as assessed by fluorescence PCR but a different mutation at the nucleotide level. This can be done by Sanger sequencing or multiplex sequencing as described in
Step 65.
Identification of heterozygote adults from the F 1 generation and genotyping of subsequent generations by fluorescence pcr • tIMInG 1-2 d 57| Perform fin amputations (Fig. 7) using a protocol approved by the applicable animal care and use committee, and place each sample into a well of a 96-well plate. We recommend up to 94 fin amputations per plate, leaving wells for a positive (WT DNA) and negative (no DNA) control.
58| Extract genomic DNA from the fin tissue as described in Box 2.
59| Add 60 µl of primer mix (
Step 37) to a 1-ml aliquot of PCR master mix.
60|
Using a fresh 96-well plate, add 10 µl of the PCR master mix/primer mix to each well.
61| Add 3 µl of diluted DNA to each well. Vortex the plate and briefly spin it down.
62|
Run fluorescence PCR and capillary electrophoresis as described in Steps 41-45. Store the remaining PCR mixture at −20 °C for up to 1 month for follow-up sequencing.
63|
Load the plate onto an ABI 3130xl or 3730xl genetic analyzer, and run it using the Fragment Analysis module parameters (supplementary table 2 64| After the run is complete, analyze the data using the GeneMapper Software package to determine the mutation in each fish (Fig. 6) . The difference in size between the two alleles is the size of the insertion or deletion.
sequencing of targeted loci • tIMInG 1-2 d 65| Verify mutation sequences using Sanger sequencing (option A) or barcoded multiplex sequencing (option B). Sanger sequencing (option A) is the preferred method for low-throughput applications, whereas barcoded multiplex sequencing (option B) is preferred for high-throughput applications. (vi) Clean up the reactions using Qiagen DyeEx plates according to the manufacturer's instructions, and run purified samples on an ABI 3130xl or 3730xl genetic analyzer using standard sequencing programs. (vii) Analyze the heterozygous sequence (Fig. 8) 70| Create a NovoAlign index from the FASTA file (to be submitted with the '-x' option). This can be done using the NovoIndex program, which can be downloaded along with NovoAlign: novoindex desired_index_name.nix ~/path/to/amplicon_fasta.fa
Other gap-aware aligners such as BWA or Bowtie2 are also options, but one needs to modify the 'sh/novoalign.sh' file and create an appropriate index from the FASTA file. This will take less than 1 min for small files (~1 Mbp sequences) and ~1 h for a 2 Gbp genome.
71| (Optional) Create the ranges file (to be submitted with the '-r' option). This is useful if one is interested only in deletion and insertion variants (DIVs) that appear within a certain window of the amplicon sequence. The file should have three columns. The first column is the ID of the amplicon, and it must match the third column in the barcode file. The second and third columns are the beginning and end of the window of interest, respectively, and should both be 1-based coordinates. Here are some example lines: The first column is the amplicon ID, but it is not required to match the formatting used in the barcode file from Step 68. Note that colons are permissible. The second and third columns are the sequences of the primers used to amplify the long amplicons. Both are written 5′ to 3′.
73|
Run the program within the ampliconDIVider/ directory. Doing so will create a working directory in which the intermediate files will be kept; upon completion of the program, an output directory will be created to hold the final results. When running the program, it is recommended that the '-l' and '-n' options be used. '-l' automatically calculates the read length and mean and standard deviation of the fragment length, and '-n' allows you to specify a name for the working directory. The example BAM included in the repository can be used to test the script:
/ampliconDIVider_driver.sh -l -b Varshney_et_al_input/set1_barcodes -n example -p Varshney_et_al_input/set1_long_fragments -r Varshney_et_al_input/set1_ranges -f
Varshney_et_al_input/set1_amplicons.fa -x ~/path/to/set1_amplicons.nix example.bam
When running the program with your own data, replace these files with your own. Runtime is ~1 d for ~13 M short read pairs.
74|
Interpret the output using the information provided in Box 3.
? trouBlesHootInG Troubleshooting advice can be found in table 1. Clone the PCR product and sequence clones to identify exact mutation
